journal article·2020-11

Piroxicam ternary solid dispersion system for improvement of dissolution (%) and in vitro anti-inflammation effects

Jeong Sun Sohn, Eui Jin Kim, Ji-Won Park, Jin-Seok Choi

Publisher page

Abstract

Abstract The improvement of drug solubility is a challenging task in the pharmaceutical industry; moreover, drug stability is also important. This study was designed to improve the dissolution (%) and in vitro anti-inflammation effects of piroxicam (PRX) and maintain its stability using a ternary solid dispersion (SD) system. The solubilizer (poloxamer 407 [P407®]) and carrier (Aerosil®200) were selected based on solubility test and pre-dissolution test, respectively. The SD1 formulation (PRX: Aerosil®200: P407® = 1:1:3 wt ratio) improved the dissolution (%) by over 1.11-/1.17-/1.21-fold and 1.77-/2.26-/1.39-fold compared with commercial products, Feldene® and pure PRX, respectively, in pH 1.2/distilled water/pH 6.8 buffer for 60 min, respectively. The anti-inflammation study of SD1 observed similar or improved compared to that of Feldene®. In conclusion, the SD1 was developed with significantly enhanced dissolution (%) and stability for 12 months. Thus, the SD1 is expected to improve bioavailability and be effective in anti-inflammatory treatment in animal study.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Drug Solubulity and Delivery Systems · Pharmacological Effects of Natural Compounds · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (34)

Show source-provided references
1. Biopharmaceutical classification of poorly soluble drugs with respect to “enabling formulations”10.1016/j.ejps.2013.04.002 ↗
2. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs10.1016/j.drudis.2007.09.005 ↗
3. Comparison of paclitaxel solid dispersion and polymeric micelles for improved oral bioavailability and in vitro anti-cancer effects10.1016/j.msec.2019.03.002 ↗
4. Improvement of the dissolution rate and bioavailability of fenofibrate by the supercritical anti-solvent process10.1016/j.ijpharm.2019.04.051 ↗
5. F. ud Din, A. Zeb, K.U. Shah, Development, in-vitro and in-vivo evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product, J. Drug. Deliv. Sci. Technol. 51 (2019) 583-590.10.1016/j.jddst.2019.02.026 ↗
6. Surface modification of docetaxel nanocrystals with HER2 antibody to enhance cell growth inhibition in breast cancer cells10.1016/j.colsurfb.2017.07.064 ↗
7. Design of cilostazol nanocrystals for improved solubility
8. Development of surface curcumin nanoparticles modified with biological macromolecules for anti-tumor effects10.1016/j.ijbiomac.2016.07.101 ↗
9. Comparison of adsorption and conjugation of Herceptin on poly (lactic-co-glycolic acid) nanoparticles–Effect on cell internalization in breast cancer cells10.1016/j.msec.2018.06.059 ↗
10. Systematic evaluation of multifunctional paclitaxel-loaded polymeric mixed micelles as a potential anticancer remedy to overcome multidrug resistance10.1016/j.actbio.2016.12.021 ↗
11. J.-S. Choi, D.-H. Lee, J.B. Ahn, S. Sim, K.-S. Heo, C.-S. Myung, J.-S. Park, Therapeutic effects of celecoxib polymeric systems in rat models of inflammation and adjuvant-induced rheumatoid arthritis, Mater. Sci. Eng. C. DOI (2020) 111042.10.1016/j.msec.2020.111042 ↗
12. Pharmacokinetics and tissue distribution of docetaxel liposome mediated by a novel galactosylated cholesterol derivatives synthesized by lipase-catalyzed esterification in non-aqueous phase10.3109/10717544.2014.980525 ↗
13. Ultrasound influence on the solubility of solid dispersions prepared for a poorly soluble drug10.1016/j.ultsonch.2015.10.022 ↗
14. Characteristics of piroxicam granules prepared by fluidized bed hot melt granulation10.1016/j.apt.2018.01.011 ↗
15. Solid-state, triboelectrostatic and dissolution characteristics of spray-dried piroxicam-glucosamine solid dispersions10.1016/j.colsurfb.2016.07.032 ↗
16. Amorphous solid dispersions of piroxicam and Soluplus®: Qualitative and quantitative analysis of piroxicam recrystallization during storage10.1016/j.ijpharm.2015.03.079 ↗
17. Towards improved solubility of poorly water-soluble drugs: cryogenic co-grinding of piroxicam with carrier polymers10.3109/03639045.2015.1054400 ↗
18. Enhanced transdermal permeability of piroxicam through novel nanoemulgel formulation10.4103/2230-973X.133053 ↗
19. Fabrication and evaluation of Eudragit® polymeric films for transdermal delivery of piroxicam10.1080/10837450.2017.1319864 ↗
20. Simultaneous electrochemical determination of levodopa and piroxicam using a glassy carbon electrode modified with a ZnO–Pd/CNT nanocomposite10.1039/C8RA03460E ↗
21. Pharmaceutical cocrystal of piroxicam: design, formulation and evaluation10.15171/apb.2017.048 ↗
22. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying10.1016/j.ijpharm.2014.03.047 ↗
23. Amorphous multi-system of celecoxib improves its anti-inflammatory activity in vitro and oral absorption in rats10.1016/j.ijpharm.2018.11.050 ↗
24. Enhanced bioavailability of piroxicam via salt formation with ethanolamines
25. Preparation and characterization of piroxicam/poloxamer solid dispersion prepared by melting method and solvent method10.4333/KPS.2007.37.1.001 ↗
26. Enhanced dissolution and oral bioavailability of piroxicam formulations: modulating effect of phospholipids10.3390/pharmaceutics2040339 ↗
27. Water-mediated solid-state transformation of a polymorphic drug during aqueous-based drug-layer coating of pellets10.1016/j.ijpharm.2013.08.036 ↗
28. Fast dissolving cyclodextrin complex of piroxicam in solid dispersion Part I: Influence of β-CD and HPβ-CD on the dissolution rate of piroxicam10.1016/j.ijpharm.2014.12.019 ↗
29. Design of Coenzyme Q10 solid dispersion for improved solubilization and stability10.1016/j.ijpharm.2019.118832 ↗
30. Naftopidil-fumaric acid interaction in a solid dispersion system: improving the dissolution rate and oral absorption of naftopidil in rats10.1016/j.msec.2018.10.089 ↗
31. Solid dispersion of dutasteride using the solvent evaporation method: approaches to improve dissolution rate and oral bioavailability in rats10.1016/j.msec.2018.04.074 ↗
32. Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation10.1016/S0939-6411(03)00142-5 ↗
33. Continuous production of itraconazole-based solid dispersions by hot melt extrusion: preformulation, optimization and design space determination10.1016/j.ijpharm.2016.10.003 ↗
34. Crystal modifications and dissolution rate of piroxicam10.2478/v10007-011-0037-z ↗